Cannabis Hyperemesis Syndrome (CHS) is an under-recognized cause of severe, recurrent vomiting in young people who use cannabis heavily and regularly. A new narrative review consolidates available evidence on the condition’s three clinical phases, diagnostic pitfalls, and treatment, but the research base remains thin, built largely on case reports. Stopping cannabis use is the only reliably effective treatment, and clinicians should consider CHS in any young patient presenting with unexplained cyclical vomiting.

Cannabis use among adolescents and young adults is at historically elevated levels in many countries, and the average THC concentration in available products has increased roughly fourfold since the 1980s. CHS remains poorly recognized by emergency physicians, pediatricians, and primary care providers, frequently leading to misdiagnosis as cyclic vomiting syndrome, eating disorders, or other gastrointestinal conditions. These diagnostic delays expose young patients to unnecessary invasive testing, prolonged suffering, and avoidable emergency department visits. Improving clinical awareness of this condition is increasingly urgent as legalization expands access and normalizes use among younger populations.

Cannabis Hyperemesis Syndrome was first described in 2004 and has since emerged as a distinct clinical entity tied to chronic, heavy cannabis use. The condition is thought to arise from prolonged cannabinoid receptor activation in the gastrointestinal tract, disrupting normal motility and emetic regulation. This narrative review examines 13 primary studies published between 2004 and 2024, drawing on PubMed and Google Scholar searches conducted from October 2024 through March 2025. The included literature spans six case reports, three case series, one randomized controlled trial, one longitudinal analysis, one repeated cross-sectional study, and one qualitative investigation. The review organizes its findings across six thematic areas: clinical presentation, diagnosis, treatment, youth-specific vulnerability, the role of increasing THC potency, and public health implications.

The review describes CHS as progressing through three identifiable phases: a prodromal phase marked by early morning nausea that patients often self-treat with additional cannabis; a hyperemetic phase involving severe, protracted vomiting, dehydration, electrolyte disturbances, and the characteristic compulsion to take hot showers or baths for temporary relief; and a recovery phase in which symptoms resolve following cannabis cessation. A referenced systematic review identified only 24 adolescent CHS patients across 21 studies, underscoring the critically thin evidence base for this age group. An Ontario-based observational study found a 60% higher rate of CHS-related emergency visits post-legalization (IRR 1.60, 95% CI 1.19 to 2.16). Cannabis cessation remains the only definitive treatment, with topical capsaicin offered as a symptomatic adjunct. The authors recommend improved provider education, school-based prevention programs, and targeted public health campaigns, though these recommendations rest on expert synthesis rather than intervention trials.

This review does an important service by consolidating what we know about CHS in young people into a single, readable document. The clinical phasing is accurate and clinically useful, and the emphasis on misdiagnosis resonates with what I see regularly. Where I would urge caution is in the gap between the review’s advocacy tone and the reality of the evidence underneath it. Thirteen studies, most of them case reports involving handfuls of patients, cannot support population-level claims about incidence trends or the causal role of legalization. The Ontario emergency department data are suggestive but represent a single jurisdiction and a correlational finding.

In practice, I see CHS-like presentations with some regularity among young patients who use cannabis daily. The conversation I find most productive is not about fear or prohibition but about frequency and dose. I counsel patients directly that daily, high-potency use carries real gastrointestinal risk, and I make sure they understand that hot showers providing temporary relief is a red flag, not a solution. When a patient is willing to try a structured cannabis holiday, we track symptoms closely. For those who are not ready to stop, harm reduction through lower-potency products and reduced frequency is a practical starting point, even though the evidence for partial dose reduction in CHS is essentially nonexistent.

This review sits at an early point in the research arc for CHS in youth. The syndrome itself is well-described clinically, but the pediatric and adolescent literature remains dominated by case-level evidence. We do not yet have prospective cohort data, validated screening tools, or dose-response curves that would allow clinicians to identify which young users are at highest risk. The observation that females may be disproportionately represented among adolescent CHS cases is intriguing but is drawn from a systematic review of only 24 patients and cannot be considered reliable. Clinicians should recognize CHS as a diagnosis of exclusion that becomes more likely when a young patient with heavy cannabis use presents with cyclical vomiting, early morning nausea, and relief from hot bathing, but should still complete appropriate workup for other etiologies.

From a pharmacological standpoint, the review highlights topical capsaicin cream applied to the abdomen as an

Physician-Led, Whole-Person Care

A doctor who takes the time to truly understand you.

Personal care that starts with listening and is guided by experience and ingenuity.

Health, Longevity, Wellness

One-on-One Cannabis Guidance

Metabolic Balance

Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care